MA5-13877

antibody from Invitrogen Antibodies

Targeting: EGFR ERBB, ERBB1

Provider product page for MA5-13877

Western blot

Other assay

Antibody data

Antibody Data
Antigen structure
References [27]
Comments [0]
Validations
Western blot [1]
Other assay [3]

Submit

Product number: MA5-13877 - Provider product page
Provider: Invitrogen Antibodies
Product name: EGFR Monoclonal Antibody (H9B4)
Antibody type: Monoclonal
Antigen: Purifed from natural sources
Description: MA5-13877 targets Epidermal Growth Factor Receptor in IP and WB applications and shows reactivity with Human samples.
Antibody clone number: H9B4
Concentration: 0.2 mg/mL

EGFR protein structure - MA5-13877 shown in red.

Submitted references Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current.

Hernández-Bule ML, Martínez MA, Trillo MÁ, Martínez L, Toledano-Macías E, Úbeda A
Oncology letters 2021 Nov;22(5):807

Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.

Tamura S, Wang Y, Veeneman B, Hovelson D, Bankhead A 3rd, Broses LJ, Lorenzatti Hiles G, Liebert M, Rubin JR, Day KC, Hussain M, Neamati N, Tomlins S, Palmbos PL, Grivas P, Day ML
Bladder cancer (Amsterdam, Netherlands) 2018 Jan 20;4(1):77-90

HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.

Day KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, Shah R, Kunja LP, Hall C, Palanisamy N, Daignault-Newton S, El-Sawy L, Wilson SJ, Chou A, Ignatoski KW, Keller E, Thomas D, Nagrath S, Morgan T, Day ML
Cancer research 2017 Jan 1;77(1):74-85

Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation.

Wu Y, Wang Y, Lin Y, Liu Y, Wang Y, Jia J, Singh P, Chi YI, Wang C, Dong C, Li W, Tao M, Napier D, Shi Q, Deng J, Evers BM, Zhou BP
Nature communications 2017 Feb 15;8:14228

MUC1 stimulates EGFR expression and function in endometrial cancer.

Engel BJ, Bowser JL, Broaddus RR, Carson DD
Oncotarget 2016 May 31;7(22):32796-809

EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.

Arasada RR, Amann JM, Rahman MA, Huppert SS, Carbone DP
Cancer research 2014 Oct 1;74(19):5572-84

Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.

Brouxhon SM, Kyrkanides S, Teng X, O'Banion MK, Clarke R, Byers S, Ma L
Molecular carcinogenesis 2014 Nov;53(11):893-906

Metastasis suppressor tetraspanin CD82/KAI1 regulates ubiquitylation of epidermal growth factor receptor.

Odintsova E, van Niel G, Conjeaud H, Raposo G, Iwamoto R, Mekada E, Berditchevski F
The Journal of biological chemistry 2013 Sep 6;288(36):26323-26334

Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines.

Neeraja Dharmaraj, Engel BJ, Carson DD
Journal of cellular biochemistry 2013 Oct;114(10):2314-22

Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.

Grivas PD, Day KC, Karatsinides A, Paul A, Shakir N, Owainati I, Liebert M, Kunju LP, Thomas D, Hussain M, Day ML
Molecular medicine (Cambridge, Mass.) 2013 Nov 8;19(1):367-76

The MUC1 Ectodomain: A Novel and Efficient Target for Gold Nanoparticle Clustering and Vapor Nanobubble Generation.

Danysh BP, Constantinou PE, Lukianova-Hleb EY, Lapotko DO, Carson DD
Theranostics 2012;2(8):777-87

EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.

Grabowska MM, Sandhu B, Day ML
Cellular signalling 2012 Feb;24(2):532-8

Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.

Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Jordan VC
European journal of cancer (Oxford, England : 1990) 2012 Dec;48(18):3488-98

Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.

DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Breast cancer research : BCR 2011 Apr 15;13(2):R44

A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.

Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J, Goodman L, Whitcomb J, Petropoulos C, Winslow J
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2009 Mar;18(1):11-21

Pregnancy-upregulated nonubiquitous calmodulin kinase induces ligand-independent EGFR degradation.

Deb TB, Coticchia CM, Barndt R, Zuo H, Dickson RB, Johnson MD
American journal of physiology. Cell physiology 2008 Aug;295(2):C365-77

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.

Choi SH, Mendrola JM, Lemmon MA
Oncogene 2007 Mar 8;26(11):1567-76

Targeting EGFR in bladder cancer.

Villares GJ, Zigler M, Blehm K, Bogdan C, McConkey D, Colin D, Bar-Eli M
World journal of urology 2007 Dec;25(6):573-9

Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR.

Kraemer K, Schmidt U, Fuessel S, Herr A, Wirth MP, Meye A
International journal of cancer 2006 Sep 15;119(6):1276-84

ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells.

Contessa JN, Abell A, Valerie K, Lin PS, Schmidt-Ullrich RK
International journal of radiation oncology, biology, physics 2006 Jul 1;65(3):851-8

Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.

Contessa JN, Abell A, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK
Breast cancer research and treatment 2006 Jan;95(1):17-27

Gangliosides play an important role in the organization of CD82-enriched microdomains.

Odintsova E, Butters TD, Monti E, Sprong H, van Meer G, Berditchevski F
The Biochemical journal 2006 Dec 1;400(2):315-25

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Aug 1;12(15):4671-7

Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface.

Dawson JP, Berger MB, Lin CC, Schlessinger J, Lemmon MA, Ferguson KM
Molecular and cellular biology 2005 Sep;25(17):7734-42

Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes.

Kansra S, Stoll SW, Johnson JL, Elder JT
Molecular pharmacology 2005 Apr;67(4):1145-57

Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2.

Sturla LM, Amorino G, Alexander MS, Mikkelsen RB, Valerie K, Schmidt-Ullrichr RK
The Journal of biological chemistry 2005 Apr 15;280(15):14597-604

Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle.

Genther SM, Sterling S, Duensing S, Münger K, Sattler C, Lambert PF
Journal of virology 2003 Mar;77(5):2832-42

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis was performed on whole cell extracts (30 µg lysate) of A431 (Lane 1), A549 (Lane 2) and HeLa (Lane 3). The blots were probed with Anti-EGFR Mouse Monoclonal Antibody (Product # MA5-13877, 1-3 µg/mL) and detected by chemiluminescence Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP conjugate (Product # 62-6520, 1:4000 dilution). A 180 kDa band corresponding to EGFR was observed across cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel (Product # NP0301BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with by overnight wet transfer method. The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation of Epidermal Growth Factor Receptor using Epidermal Growth Factor Receptor Monoclonal Antibody (Product # MA5-13877) on Native Human A431 Cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation of Epidermal Growth Factor Receptor using Epidermal Growth Factor Receptor Monoclonal Antibody (Product # MA5-13877) on denatured Human A431 Cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4. Effect of CRET and/or sorafenib on EGFR and ERK expression and activation. Western blotting results for p-ERK, ERK, p-EGFR and EGFR expression are presented. The samples were treated with CRET alone (4 h intermittent exposure), sorafenib alone (4 h) or in combination. Data are presented as the ratio of (A) p-ERK1/2 over total ERK1/2 protein and (B) p-EGFR over total EGFR protein. Data are presented as the mean +- SEM of >=3 experimental replicates. *P